A pilot study of the effect of pullulan-conjugated Der f 2 allergen-specific immunotherapy on canine atopic dermatitis

2017 ◽  
Vol 28 (6) ◽  
pp. 583-e141 ◽  
Author(s):  
Kouji Kawano ◽  
Takuya Mizuno
Keyword(s):  
Atopic Dermatitis ◽  
Pilot Study ◽  
Specific Immunotherapy ◽  
Allergen Specific Immunotherapy ◽  
Canine Atopic Dermatitis

Supplementary therapy in canine atopic dermatitis

2019 ◽  
Vol 24 (8) ◽  
pp. 400-407
Author(s):  
Sue Paterson
Keyword(s):  
Fatty Acids ◽  
Atopic Dermatitis ◽  
Specific Immunotherapy ◽  
Essential Fatty Acids ◽  
Topical Therapy ◽  
Allergen Specific Immunotherapy ◽  
Canine Atopic Dermatitis ◽  
Adequate Control ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Therapy for canine atopic dermatitis can be described as foundation or supplementary. Foundation therapy, which refers to allergen-specific immunotherapy, ciclosporin, glucocorticoids, lokivetmab and oclacitinib, is needed in all but the mildest of cases of canine atopic dermatitis. Supplementary therapies include drugs such as antihistamines, essential fatty acids, topical therapy and other systemic anti-inflammatory drugs. While it is uncommon for any of these supplementary drugs to provide adequate control of many cases of canine atopic dermatitis, they can reduce the frequency of relapse and reduce the amount of foundation therapy that is required when used in combination with them.

Foundation therapy in canine atopic dermatitis

2019 ◽  
Vol 24 (7) ◽  
pp. 347-352
Author(s):  
Sue Paterson
Keyword(s):  
Fatty Acids ◽  
Atopic Dermatitis ◽  
Strong Evidence ◽  
Specific Immunotherapy ◽  
Essential Fatty Acids ◽  
Evidence Base ◽  
Allergen Specific Immunotherapy ◽  
Canine Atopic Dermatitis ◽  
Topical Emollient ◽  
Risk Of Relapse

Therapy in canine atopic dermatitis should be multimodal and should be individualised for each patient. Therapies can be described as foundation or supplementary. In all but the mildest cases, dogs require a foundation therapy for the control of their atopic dermatitis. These include allergen-specific immunotherapy, ciclosporin, glucocorticoids, lokivetmab or oclacitinib. All of these five therapeutic options have a strong evidence base to recommend their use in canine atopic dermatitis. Supplementary therapies, which include drugs such as antihistamines, essential fatty acids, topical emollient and antiseptics, help in treatment to improve barrier function and correct skin biome dysbiosis, but can rarely control canine atopic dermatitis in isolation. When combined with foundation therapy they can reduce the risk of relapse and the level of foundation therapy that is required. https://doi.org/10.12968/coan.2019.0020

Management of canine atopic dermatitis

2020 ◽  
Vol 25 (6) ◽  
pp. 162-167
Author(s):  
Hannah Lipscomb ◽  
Filippo De Bellis
Keyword(s):  
Atopic Dermatitis ◽  
Specific Immunotherapy ◽  
Clinical Signs ◽  
Term Treatment ◽  
Allergen Specific Immunotherapy ◽  
Canine Atopic Dermatitis ◽  
Long Term Treatment ◽  
Fast Acting ◽  
Oral Glucocorticoids

Canine atopic dermatitis can present in two different ways — acute versus chronic — which require different treatment. When dealing with an acute flare, it is important to try and identify and eliminate the trigger and then provide fast-acting topical and/or systemic treatment. The treatment of chronic atopic dermatitis differs as it includes identification of flare factors, treatment of pruritus and prevention strategies. For long-term treatment of pruritus, there are currently four licenced prescription options available: oral glucocorticoids, oral ciclosporin, oral oclacitinib and injectable lokivetmab. The key prevention strategy for canine atopic dermatitis is allergen-specific immunotherapy and it is currently the only treatment that may induce complete remission of clinical signs. Alongside treatment for cases of canine atopic dermatitis, it is important to effectively communicate with clients in order to achieve compliance and medical adherence.

Sign in / Sign up

Export Citation Format

Share Document